EU Accelerated Assessment Tracker
Will Novartis's Capmatinib Be Fast-Tracked Once It Is Filed?
Novartis is trying its luck with capmatinib on the accelerated assessment front at the European Medicines Agency. Gilead and Astellas/Seagen have secured fast-track review for their respective potential new products while Sesen Bio and Amryt Pharma are dealing with rejection.